Loading provider…
Loading provider…
Hematology (Internal Medicine) Physician in Port Jefferson Station, NY
NPI: 1285605998Primary Employer
Port Jefferson Station Medical Oncology
nycancer.com
HQ Phone
Get MD David's Phone Numberphone_androidMobile
Get MD David's MobileLooking to connect with more Physicians?
Dmand AI gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Get Started for Freearrow_outwardCA State Medical License
1974
FL State Medical License
2022
NY State Medical License
1970 - 2027
NJ State Medical License
2023
NY State Medical License

American Board of Internal Medicine
Internal Medicine

American Board of Internal Medicine
Hematology

American Board of Internal Medicine
Medical Oncology
Medical College Of Wisconsin
mcw.edu
Medical School
Until 1969
Memorial Sloan Kettering Cancer Center
Fellowship • Hematology and Medical Oncology
1975 - 1977
Beth Israel Deaconess Medical Center
Fellowship • Hematology and Medical Oncology
1972 - 1973
Montefiore Medical Center/Albert Einstein College of Medicine (Moses and Weiler Campuses)
Residency • Internal Medicine
1969 - 1972
| # | Procedure Code (CPT®/HCPCS II) | Procedure Patients | Procedure Volume |
|---|---|---|---|
| 1 | 36415Insertion of needle into vein for collection of blood sample | 65 | 106 |
| 2 | 85025Complete blood cell count (red cells, white blood cell, platelets), automated test | 64 | 104 |
| 3 | 99214Established patient office or other outpatient visit, 30-39 minutes | 61 | 78 |
| 4 | 80053Blood test, comprehensive group of blood chemicals | 56 | 78 |
| 5 | 99213Established patient office or other outpatient visit, typically 15 minutes | 55 | 58 |
PET-adapted sequential salvage therapy with brentuximab vedotin followed by augmented ifosamide, carboplatin, and etoposide for patients with relapsed and refractory Hodgkin's lymphoma: a non-randomised, open-label, single-centre, phase 2 study.
Authors: Paul Hamlin, Carol Portlock, Ariela Noy, Anita Kumar, Peter Steinherz, Rachel Kobos, Matthew Matasar, Anita Kumar, Ravinder Grewal
Publication Date: 2015-02-17
Authors: Philip Caron, Lorenzo Falchi, Anna Alperovich, Steven Horwitz, Connie Batlevi, Colette Owens, Craig Moskowitz, Paul Hamlin, Audrey Hamilton, Ariela Noy, Andrew Zelenetz, Alison Moskowitz, Gottfried Von Keudell
Journal: Blood Cancer J
Publication Date: 2020-07-17
The non-Hodgkin's lymphomas. I. A retrospective clinical and pathologic analysis of 499 cases diagnosed between 1958 and 1969.
Authors: David J. Straus, Daniel A. Filippa, Philip H. Lieberman, Benjamin Koziner, H. Tzvi Thaler, Bayard D. Clarkson
Publication Date: 1983-01
Lead Sponsor: Alliance for Clinical Trials in Oncology
Collaborators: National Cancer Institute (NCI)
Intervention / Treatment: PROCEDURE: Positron Emission Tomography, PROCEDURE: computed tomography, DRUG: Cyclophosphamide, DRUG: Dacarbazine, DRUG: prednisone, RADIATION: Fludeoxyglucose F-18, BIOLOGICAL: Bleomycin Sulfate, DRUG: Radiation Therapy, DRUG: Etoposide phosphate, DRUG: Vinblastine Sulfate, DRUG: Doxorubicin Hydrochloride, DRUG: Procarbazine Hydrochloride
Lead Sponsor: SWOG Cancer Research Network
Collaborators: National Cancer Institute (NCI)
Intervention / Treatment: DRUG: dacarbazine, BIOLOGICAL: filgrastim, DRUG: prednisone, DRUG: doxorubicin hydrochloride, BIOLOGICAL: bleomycin sulfate, DRUG: cyclophosphamide, DRUG: etoposide, DRUG: vincristine sulfate, DRUG: vinblastine sulfate, DRUG: ABVD regimen, DRUG: BEACOPP regimen, DRUG: procarbazine hydrochloride
Lead Sponsor: Memorial Sloan Kettering Cancer Center
Collaborators: Merck Sharp & Dohme LLC, Northwestern University, Weill Medical College of Cornell University, Endeavor Health
Intervention / Treatment: DRUG: rituximab, cyclophosphamide, etoposide, prednisone, vorinostat and QOL questionnaire, peg-filgrastim or filgrastim